Lexeo Therapeutics (LXEO) investor relations material

Executive summary

• Lead gene therapy candidates LX2006 (FA cardiomyopathy) and LX2020 (PKP2-ACM) advanced in Phase 1/2 trials, with LX2006 pivotal trial protocol submitted to FDA and initiation planned for Q2 2026.

• LX2006 showed sustained improvements in cardiac and neurologic measures, with regulatory alignment for accelerated approval and Breakthrough Therapy designation.

• LX2020 interim data indicated dose-dependent improvements in arrhythmia burden and PKP2 protein expression, with favorable safety profile and further regulatory engagement planned.

• Showcased preclinical proof-of-concept for LX2022 in a novel porcine model of hypertrophic cardiomyopathy.

• Appointed Laura Sepp-Lorenzino, Ph.D., to the Board of Directors.

Financial highlights

• Net loss for Q1 2026 was $20.2 million ($0.25 per share), compared to $32.7 million ($0.99 per share) in Q1 2025.

• Operating expenses decreased to $22.3 million from $33.8 million year-over-year, driven by lower R&D and G&A costs.

• Cash, cash equivalents, and investments totaled $227.6 million as of March 31, 2026, expected to fund operations into 2028.

• Stockholders’ equity was $231.5 million at quarter-end.

• Interest income increased to $2.1 million from $1.2 million year-over-year.

Outlook and guidance

• Cash runway expected to fund operations into 2028.

• Plans to initiate pivotal study for LX2006 in Q2 2026, pending FDA feedback; 12-month data update for LX2020 high dose participants expected in Q4 2026.

• Anticipates continued net operating losses and increased R&D and G&A expenses as clinical programs advance.

• Regulatory engagement for LX2020 expected in 2026.